Jennifer Amengual

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Jennifer Amengual sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 1 currently recruiting 1 completed early-phase tilt upper quartile by trial count

Jennifer Amengual: 3 sponsored US clinical trials, 1 recruiting.

Jennifer Amengual sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, with 2 trials.

Upper-quartile sponsor footprint

Jennifer Amengual sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Jennifer Amengual pipeline

1 recruiting of 3 indexed (33% open); 1 completed (33%).

Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).

Top condition: Lymphoma (2 trials), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Jennifer Amengual: open-pipeline peers nationwide

Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Jennifer Amengual sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%10%20%30%40% Total trials Recruiting share Jennifer Amengual10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAadi BioscienceAaron CookAbivax S.A.Actuated Medical
Jennifer Amengual sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Jennifer Amengual sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

What to do with this Jennifer Amengual page

3 registered trials is a research-attention snapshot, not an endorsement of Jennifer Amengual or any single study.

  • 1 of Jennifer Amengual's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Lymphoma is the condition Jennifer Amengual studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Jennifer Amengual pipeline card: 3 registered trials from official public datasets.Report a data error.